Towards personalized therapy for patients with malignant melanoma: Molecular insights into the biology of BRAF mutations

Joshua R. Bradish, Rodolfo Montironi, Antonio Lopez-Beltran, Kristin M. Post, Gregory T. MacLennan, Liang Cheng

Research output: Contribution to journalReview article

11 Scopus citations

Abstract

BRAF mutations have been identified as the most common oncogene mutation in melanomas, especially important in those originating on nonchronically sun-damaged skin. There is a large and continually growing body of evidence regarding the importance of this mutation in targeted therapy for melanoma. In this review, we outline these findings including: molecular pathways used by BRAF, the importance in nonmalignant neoplasms, histologic associations, the relationship of BRAF to KIT and NRAS mutations, and their impact on survival, as well as resistance mechanisms to BRAF inhibitors employed by melanoma. Understanding these topics and how they relate to one another may facilitate the development of new treatments and eventually improve the prognosis for those patients afflicted with this disease.

Original languageEnglish (US)
Pages (from-to)245-253
Number of pages9
JournalFuture Oncology
Volume9
Issue number2
DOIs
StatePublished - Feb 1 2013

Keywords

  • BRAF mutation
  • KIT mutation
  • malignant melanoma
  • metastasis
  • NRAS mutation
  • pathway targeting
  • personalized medicine
  • targeted therapy

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Towards personalized therapy for patients with malignant melanoma: Molecular insights into the biology of BRAF mutations'. Together they form a unique fingerprint.

  • Cite this